Skip to main content

Table 3 Cost-effectiveness results

From: Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme

Sensitivity analyses

Screening

No screening

Incremental

Total Costs (m)

Total QALYs

Total Costs (m)

Total QALYs

Costs (m)

95% Confidence Interval (m)

QALYs

95% Confidence Interval

ICER

Base case

£3.01

390

£6.44

307

-£3.04

(−£5.69, −£1.19)

82

(43, 139)

Dominates

Incidence rate doubled

£5.97

778

£12.88

614

-£6.50

(−£11.74, −£2.80)

164

(86, 277)

Dominates

Incidence rate halved

£1.51

194

£3.21

153

-£1.30

(−£2.62, −£0.39)

41

(22, 69)

Dominates

CCALD 10% of total X-ALD

£2.02

412

£2.21

397

£0.21

(−£0.06, £0.46)

16

(9, 24)

£13,600

CCALD 15% of total X-ALD

£2.13

409

£2.70

386

-£0.17

(−£0.63, £0.22)

23

(14, 36)

Dominates

CCALD 60% HSCT rate

£5.20

340

£6.41

307

-£0.81

(−£2.01, £0.02)

33

(15, 60)

Dominates

CCALD 10% of total X-ALD and 80% HSCT rate

£2.23

407

£2.21

396

£0.42

(£0.24, £0.62)

11

(6, 17)

£38,701

CCALD 15% of total X-ALD and 80% HSCT rate

£2.43

401

£2.69

385

£0.15

(−£0.18, £0.42)

16

(9, 26)

£8927

CCALD 20% of total X-ALD and 80% HSCT rate

£2.65

396

£3.18

375

-£0.12

(−£0.59, £0.24)

22

(13, 34)

Dominates

1.5% Discount Rate

£4.59

611

£9.35

455

-£4.36

(−£7.97, −£1.81)

156

(83, 260)

Dominates

Both girls and boys screened

£3.27

800

£6.96

718

-£3.27

(−£5.97, −£1.36)

82

(43, 139)

Dominates

  1. m million